Central Trust Company’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Central Trust Company’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-750	Closed	-$36K	–	1119
2020 Q2	$36K	Hold	750	–	–	﹤0.01%	671
2020 Q1	$47K	Hold	750	–	–	﹤0.01%	621
2019 Q4	$93K	Hold	750	–	–	﹤0.01%	584
2019 Q3	$50K	Hold	750	–	–	﹤0.01%	650
2019 Q2	$54K	Hold	750	–	–	﹤0.01%	639
2019 Q1	$84K	Hold	750	–	–	0.01%	558
2018 Q4	$76K	Hold	750	–	–	0.01%	566
2018 Q3	$95K	Hold	750	–	–	0.01%	579
2018 Q2	$63K	Hold	750	–	–	﹤0.01%	633
2018 Q1	$46K	Hold	750	–	–	﹤0.01%	700
2017 Q4	$44K	Hold	750	–	–	﹤0.01%	729
2017 Q3	$44K	Hold	750	–	–	﹤0.01%	707
2017 Q2	$91K	Hold	750	–	–	0.01%	577
2017 Q1	$85K	Hold	750	–	–	0.01%	594
2016 Q4	$81K	Hold	750	–	–	0.01%	602
2016 Q3	$123K	Hold	750	–	–	0.01%	511
2016 Q2	$107K	Buy	+750	New	+$109K	0.01%	527

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Central Trust Company's ICPT Position: Q3 2020 in Review

Central Trust Company sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2020, closing a stake of 750 shares — an estimated $36K sold.

Central Trust Company first reported a position in ICPT in Q2 2016 and held it in 17 quarters. The position peaked at $123K in Q3 2016. 177 funds tracked by Wall St. Rank hold ICPT as of Q3 2020.

Central Trust Company reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Central Trust Company sold 750 Intercept Pharmaceuticals, Inc. shares in Q3 2020, an estimated $36K.
Central Trust Company first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 17 quarters.
Central Trust Company's Intercept Pharmaceuticals, Inc. position peaked at $123K in Q3 2016.
177 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2020.

Based on Central Trust Company's 13F filing for Q3 2020, filed 22 Oct 2020.